A Double-Blind, Placebo-Controlled, Randomised, 4-Week Safety and Tolerability Study of TRx0237 in Subjects With Mild to Moderate Alzheimer's Disease on Pre-Existing Stable Acetylcholinesterase Inhibitor and/or Memantine Therapy

Trial Profile

A Double-Blind, Placebo-Controlled, Randomised, 4-Week Safety and Tolerability Study of TRx0237 in Subjects With Mild to Moderate Alzheimer's Disease on Pre-Existing Stable Acetylcholinesterase Inhibitor and/or Memantine Therapy

Discontinued
Phase of Trial: Phase II

Latest Information Update: 12 Sep 2014

At a glance

  • Drugs TRx 0237 (Primary) ; Donepezil; Galantamine; Memantine; Rivastigmine
  • Indications Alzheimer's disease
  • Focus Adverse reactions; Biomarker
  • Sponsors TauRx Therapeutics
  • Most Recent Events

    • 01 Mar 2013 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
    • 19 Dec 2012 New source identified and integrated (United Kingdom Clinical Research Network record: 12454).
    • 10 Dec 2012 Planned End Date changed from 1 Feb 2013 to 1 Jun 2013 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top